Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2017-03-29 M&A Activity
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Discussions regarding business combination
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc RELEASE' dated March 29, 2017, disclosing inside information according to Article 17 of the European Market Abuse Regulation (MAR). The content explicitly discusses 'Discussions regarding business combination' involving a potential public tender offer, which falls under merger or takeover activity. This aligns directly with the definition for M&A Activity (TAR). Although it is a regulatory disclosure (RNS), the specific subject matter (merger/takeover discussions) makes TAR the most precise classification. The document length (4705 chars) is substantial enough that it is not merely an announcement of a report (RPA), but the report/disclosure itself.
2017-03-29 English
Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)
M&A Activity Classification · 99% confidence The document is a press release dated March 24, 2017, announcing that ImmunoGen elected not to exercise a co-development option for Biotest's compound BT-062. It details the continuation of the existing license agreement and provides updates on clinical studies. This type of announcement, which communicates a specific business development (a partnership decision) rather than comprehensive financial results (like 10-K or ER) or a general regulatory filing, fits best under the 'Regulatory Filings' (RNS) category as a general corporate news release disseminated via DGAP, or potentially 'LTR' if it were a legal dispute, but here it is a commercial/alliance update. Since there is no specific category for 'Alliance Update' or 'Business Development News' that isn't financial results or management change, and it is not a formal report itself, RNS (Regulatory Filings / General Regulatory Announcements) is the most appropriate fallback for this type of market-sensitive, non-standard announcement. However, upon reviewing the definitions, this is a specific announcement about a corporate agreement/development. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is not a management change (MANG) or dividend (DIV). It is a specific business event announcement. Given the options, RNS is the general catch-all for regulatory news that doesn't fit elsewhere. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP/SHA). Therefore, RNS is selected as the best fit for a general corporate news release about a partnership decision.
2017-03-24 English
Biotest AG: Recombinant clotting factor VIII with the name Vihuma(R) approved
Legal Proceedings Report Classification · 99% confidence The document is a press release announcing a regulatory approval (Vihuma(R) approved by the European Commission) and subsequent market launch plans. It contains keywords like "DGAP-News," "Regulatory Approval," and details about a product launch. This type of announcement, which is a specific corporate update but not a comprehensive financial report (like 10-K or IR) or a general regulatory filing (RNS), fits best under the category of a general corporate announcement or news release. Since there is no specific category for 'Product Approval/Launch News,' and it is not a standard financial report, earnings release, or management discussion, it should be classified as a general Regulatory Filing (RNS) as the fallback for specific corporate news that doesn't fit other defined categories, or potentially as a general news item if RNS is reserved strictly for mandatory exchange filings. Given the options, RNS is the most appropriate catch-all for significant, non-financial, non-management-change corporate news disseminated via a news service (DGAP). However, since it is a specific corporate event announcement, and not a standard financial filing, RNS (Regulatory Filings / General Regulatory Announcements) serves as the best fit among the provided codes for a significant, non-financial corporate update.
2017-03-01 English
Investor Presentation 2017
Investor Presentation Classification · 99% confidence The document is titled "Biotest AG Company Presentation March 2017". It contains high-level financial summaries for FY 2016, market forecasts (IgG, FVIII, Albumin), strategic pillars, and detailed slides on R&D projects (IgG Next Generation, IgM Concentrate, BT-062, BT-063). This format—a presentation deck used to communicate strategy, performance, and pipeline to investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). Since it is a detailed presentation deck, IP is the most appropriate classification.
2017-03-01 English
Investor Presentation 2017
Investor Presentation Classification · 99% confidence The document is titled "Biotest AG Company Presentation March 2017". It contains high-level financial summaries for FY 2016, market forecasts (IgG, FVIII, Albumin), strategic pillars, and detailed slides on R&D projects (IgG Next Generation, IgM Concentrate, BT-062, BT-063). This format—a presentation deck used to communicate strategy, performance, and pipeline to investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). Since it is a detailed presentation deck, IP is the most appropriate classification.
2017-03-01 German
Biotest AG: Proceedings against Biotest AG have been closed
Legal Proceedings Report Classification · 98% confidence The document is a press release dated February 17, 2017, announcing that legal proceedings against Biotest AG related to Russia business have been closed following a corporate fine payment. The key phrase indicating the document type is the subject matter: 'Proceedings against Biotest AG have been closed' and the DGAP-News keyword 'Legal Matter'. This directly corresponds to the definition of a Legal Proceedings Report (LTR), which covers updates on significant lawsuits or regulatory actions. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K).
2017-02-17 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.